Loading stock data…
LFMD
$5.00+0.32 (+6.84%)
Market ClosedLast close May 1
LifeMD, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LifeMD, Inc. in the Healthcare sector is trading at $5.00. The stock is currently near its 52-week low of $2.56, remaining 1.0% below its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why LFMD maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.00
Potential Upside
5%
Whystock Fair Value$5.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platf...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$221.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
61.99%
Volume
Today's trading volume
1.14M
Recent News
LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?
LifeMD (LFMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
How The LifeMD (LFMD) Story Is Shifting Around GLP-1 Growth Plans And 2026 Expectations
LifeMD’s fair value target currently sits at US$9.88, with the latest update keeping that figure unchanged from the prior US$9.88 estimate. Analysts link this steady target to a balance between stronger views around the GLP-1 focused growth plans, user retention and the 2026 outlook, as well as ongoing questions about how concentrated the story is in the weight loss management program. As you read on, you will see how these moving pieces shape the evolving LifeMD narrative and what it could...
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and...
Hims & Hers Powers Patient-Provider Connectivity via Digital Platforms
HIMS unites telehealth, records and pharmacy fulfillment on one digital platform, adding AI tools, diagnostics and FDA-approved medicines.
Novo launches $249 Wegovy subscription, undercutting Lilly as shares fall 30%
Subscription model targets cash-pay patients via telehealth partners, offering predictable pricing and savings while Novo moves to close gap with Lilly.